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We examined the validity of the St Gallen algorithm for Japanese breast cancer patients and sought the optimal indications of
endocrine monotherapy as adjuvant systemic treatment. According to the 2005 St Gallen algorithm, endocrine responsiveness
(responsive, uncertain, or non-responsive) and recurrence risk (low, intermediate, or high) were assessed in 436 invasive breast
cancer patients, who underwent surgery and adjuvant therapy of tamoxifen alone in 1982–1993. Furthermore, intermediate-risk
patients were divided into three groups based on lymph node metastasis and number of risk factors as follows: Group A, negative
lymph node metastasis and one risk factor; Group B, negative lymph node metastasis and two to five risk factors; and Group C,
positive lymph node metastasis. Cumulative 10-year recurrence-free survival (RFS) rates of each type were calculated. Recurrence-
free survival was as follows: endocrine responsiveness; responsive: 86.0%, uncertain: 79.5%, non-responsive: 72.4%, risk category; low:
93.3%, intermediate: 84.0%, high: 59.6%, intermediate-risk patients; Group A: 93.5%, Group B: 88.2%, and Group C: 75.0%. In
conclusion, patient classification based on St Gallen algorithm appears valid in Japanese breast cancer patients. Endocrine
monotherapy may be sufficient as adjuvant treatment in the intermediate-risk patients, in which only one risk factor was present
without any metastatic involvement in lymph node.
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The algorithm for adjuvant systemic therapy proposed by St Gallen
conferences is widely applied in Japan to plan treatments for breast
cancer patients. According to St Gallen guidelines, endocrine
monotherapy is recommended as adjuvant systemic treatment for
low-risk patients and intermediate-risk patients with endocrine
responsive tumours. Three therapeutic options, that is endocrine
monotherapy, chemotherapy with endocrine therapy, and Trastu-
zumab, are applicable for intermediate-risk patients with endo-
crine responsive tumours; however, it remains obscure which
option is effective in individual cases. In intermediate-risk patients
with endocrine response uncertain tumours, there may be some
cases that are good indications of endocrine monotherapy. To
identify the optimum indication of endocrine monotherapy as
adjuvant systemic treatment for breast cancer, we examined the
long-term outcome of Japanese breast cancer patients according to
the St Gallen algorithm.
PATIENTS AND METHODS
A total of 5763 primary breast cancer patients underwent surgery
at our institute from January 1982 to December 1993. Out of these
patients, postoperative tamoxifen monotherapy was adopted for
659 patients. From these 659 patients, those with the following
conditions were excluded: non-invasive cancer; microinvasive
cancer; stage IV cancer; male patients; bilateral breast cancer; no
residual cancer in surgical material after biopsy; o6 months of
tamoxifen therapy; and death by other disease. The remaining 436
patients served as subjects in this study. Median duration of
follow-up period was 154 months (range: 120–260 months).
In each subject, tissue sections representative of the primary
lesion were embedded in paraffin, stained using haematoxylin and
eosin, and subjected to immunohistochemical staining for oestro-
gen receptor (ER), progesterone receptor (PgR), and HER2.
According to the 2005 St Gallen guidelines (Goldhirsch et al,
2005), endocrine responsiveness (responsive, uncertain, or non-
responsive) and recurrence risk (low, intermediate, or high) were
assessed. Furthermore, the intermediate risk group was subdivided
into three groups based on lymph node metastasis and number of
risk factors as follows: Group A, negative lymph node metastasis
and one risk factor; Group B, negative lymph node metastasis and
2–5 risk factors; and Group C, positive lymph node metastasis.
Cumulative disease-free survival rates were calculated and
compared.
Immunostaining
Oestrogen receptor and PgR were immunologically stained using
ER 1D5 and PgR PgR636 antibodies (DAKO Corp., Carpinteria,
CA, USA) and an automatic immunological staining machine. An
ENVISIONþ kit (DAKO Corp.) was used as a detection system.
For ER and PgR assessment, irrespective of stain intensity, positive
reactions were defined as staining in X10% of cells.
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sHER2 was immunologically stained using anti-human HER2/
neu rabbit polyclonal antibody and an automatic immunological
staining machine. The Hercep Test (DAKO Corp.) was used as a
detection system. For HER2 assessment, staining was classified in
four grades (0, 1þ,2 þ,o r3 þ) according to the Trastuzumab
Pathological Committee standards, and positive reactions were
defined as 2þ or 3þ.
Statistical analysis
Cumulative recurrence-free survival (RFS) rates were calculated by
Kaplan–Meier estimation and compared using log-rank testing.
Values of Po0.05 were considered statistically significant.
Analyses were conducted using STATISTICA (Stat Soft Japan,
Tokyo, Japan).
RESULTS
Patient characteristics
The patient characteristics are summarised in Table 1. Mean age
was 5579.7 years (range: 23–81 years) and mean tumour diameter
was 2.6371.2cm (range: non-palpable to 9.0cm). While 152
patients were premenopausal (35%), 284 patients were postmeno-
pausal (65%). Mean duration of tamoxifen administration was
34.7719.3 months (range: 6–105 months), and tamoxifen therapy
lasted for X24 months in 384 patients (88%).
Definition of endocrine responsiveness
The concept of ‘endocrine response uncertain’ was first proposed
at the 2005 St Gallen consensus meeting. That represents tumour
with uncertain responsiveness to endocrine therapy; however, the
definition has never been clarified. While the consensus report
clearly defines responsive tumours as ER(þ)/PgR(þ), tumours
with uncertain responsiveness as ER(þ)/PgR( ), and non-
responsive tumours as ER( )/PgR( ), the classification of
ER( )/PgR(þ) tumours has remained unclear (Goldhirsch et al,
2005). In the present study, we assessed the outcome of all ER and
PgR combinations to establish definitions of the three types of
endocrine responsiveness.
ER(þ)/PgR(þ) status was identified in 210 patients (48%) with
5- and 10-year RFS rates of 89.5 and 84.7% respectively. ER( )/
PgR(þ) status was present in 20 patients (5%) with 5- and 10-year
RFS rates of 100% each. ER(þ)/PgR( ) status was identified in
148 patients (34%) with 5- and 10-year RFS rates of 86.4 and 79.5%
respectively. ER( )/PgR( ) was identified in 58 patients (13%)
with 5- and 10-year RFS rates of 72.4% each. ER( )/PgR(þ)
patients were thus classified as belonging to the responsive type in
the present study.
Endocrine responsiveness
Based on the above-mentioned classification, a total of 230 patients
(53%) were identified as responsive, with 5- and 10-year RFS rates
of 90.4 and 86.0% respectively (Figure 1). Another 148 patients
(34%) were classified as uncertain, with 5- and 10-year RFS rates of
86.4 and 79.5% respectively. The remaining 58 patients (13%) were
non-responsive, with 5- and 10-year RFS rates of 72.4% each.
While no significant differences existed between responsive and
uncertain groups (P¼0.09) or between uncertain and non-
responsive groups (P¼0.25), there was a significant difference
observed between the responsive and non-responsive groups
(P¼0.01).
Risk category
Risk category was as follows: low risk in 45 patients (10%), with 5-
and 10-year RFS rates of 95.6 and 93.3% respectively; intermediate
risk in 339 patients (78%) with 5- and 10-year RFS rates of 89.1 and
84.0% respectively; and high risk in 52 patients (12%) with 5- and
10-year RFS rates of 63.5 and 59.6% respectively (Figure 2). While
no significant differences were noted between low- and inter-
mediate-risk groups (P¼0.09), significant differences were
observed between low- and high-risk groups (P¼0.00005) and
between intermediate- and high-risk groups (P¼0.00001).
Endocrine responsiveness and risk category
Table 2 shows case number, case distribution, and 10-year
cumulative RFS rate in relation to endocrine responsiveness and
risk category. ten-year RFS rates of 90% were achieved in all low-
risk patients.
Intermediate-risk patients
Group A comprised 109 patients (32%) with 5- and 10-year RFS
rates of 95.4 and 93.5% respectively (Figure 3). Group B included
77 patients (23%) with 5- and 10-year RFS rates of 90.8 and 88.2%
respectively. Group C had 153 patients (45%) with 5- and 10-year
RFS rates of 84.3 and 75.0% respectively. While no significant
differences were seen between Groups A and B (P¼0.12) or
between Groups B and C (P¼0.05), a significant difference was
identified between Groups A and C (P¼0.0001).
Table 3 shows case number, case distribution, and 10-year
cumulative RFS rate in relation to endocrine responsiveness.
Among the intermediate-risk patients, RFS rates of 90% were
achieved in all Group A and Group B patients with endocrine
responsive tumours.
Table 1 Patient characteristics
No (%) of patients
Age
o35 years 6 (1)
X35 years 430 (99)
Pathological tumour size
p2cm 171 (39)
42cm 265 (61)
Grade
1 188 (43)
2 154 (35)
3 94 (22)
Peritumoral vascular invasion
Positive 72 (17)
Negative 364 (83)
ER
Positive 358 (82)
Negative 78 (18)
PgR
Positive 230 (53)
Negative 206 (47)
HER2
Positive (immunohistochemistry: 2+, 3+) 33 (8)
Negative (immunohistochemistry: 0, 1+) 403 (92)
Lymph nodes metastasis
Negative 231 (53)
Positive (1–3 involved nodes) 166 (38)
Positive (4 or more involved nodes) 39 (9)
ER¼oestrogen receptor; PgR¼progesterone receptor.
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sDISCUSSION
Compared to the 2003 St Gallen guidelines, the 2005 guidelines
include two major revisions to patient classification (Goldhirsch
et al, 2003, 2005). These revisions are inherited in 2007 consensus
conference (Goldhirsch et al, 2007). First revision is that endocrine
responsiveness is divided into responsive, non-responsive, and
uncertain classifications. ‘Endocrine response uncertain’ is defined
as some expression of hormone receptors either quantitatively low
or qualitatively insufficient to indicate substantial chance for
response to endocrine therapies alone. However, whether all
patients of this category need for chemotherapy or not is a matter
for argument. Second revision is that lymph node involvement is
one of the factors for risk categorisation, and risks are classified
into three grades: low, intermediate, and high. Therefore,
intermediate-risk patients accounted for large population of breast
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Figure 1 Endocrine responsiveness and long-term outcome.
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Figure 2 Risk category and long-term outcome.
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scancer cases, and several therapeutic options are available for these
patients. However, in St Gallen guidelines, there are no clear
statements how to select these options for individual patients.
A long-term outcome of Japanese breast cancer patients is
known as better than that of Western patients (Sakamoto et al,
1979). Whether the consensuses reached in Western countries are
applicable to Japanese breast cancer patients must be ascertained.
As to endocrine responsiveness, the outcome of unclassified
ER( )/PgR(þ) was assessed, and each type of endocrine
responsiveness was defined in the present study. While relatively
few ER( )/PgR(þ) cases were encountered, prognosis was
favourable. The present study thus classified ER( )/PgR(þ)
tumours as belonging to responsive tumours.
Subjects were classified based on the above study findings and
the 2005 St Gallen guidelines. In terms of endocrine responsive-
ness, prognosis was most favourable with responsive tumours,
followed by uncertain and non-responsive in that order. In terms
of risk categories, prognosis was most favourable with low-risk
tumours, followed by intermediate- and high-risk, in that order.
This confirmed that patient classification based on the 2005 St
Gallen guidelines remains valid for Japanese breast cancer patients.
In the present study, intermediate-risk patients accounted for
78% of the total subject population. We, therefore, thought that
subdivision of these patients based on lymph node metastasis and
number of risk factors was warranted. Prognosis was most
favourable with Group A (negative lymph node metastasis and
only one risk factor), followed by Group B (negative lymph node
metastasis and two to five risk factors) and Group C (positive
lymph node metastasis), in that order. Lymph node metastasis was
officially added to the 2005 St Gallen guidelines as one of the risk
factors, and the significance of this factor as the most important
prognostic factor was reaffirmed.
According to the 2005 St Gallen guidelines, either endocrine
monotherapy or no therapy is recommended as adjuvant therapy
for low-risk patients. In the present study, favourable long-term
Table 2 Endocrine responsiveness/risk category and cumulative recur-
rence-free survival (RFS)
Responsive Uncertain Non-responsive
Low
No. of cases 29 16 NA
Case distribution 7% 4%
10-year RFS 93.0% 93.8%
Intermediate
No. of cases 176 113 50
Case distribution 40% 26% 11%
10-year RFS 88.0% 81.2% 75.9%
High
No. of cases 25 19 8
Case distribution 6% 4% 2%
10-year RFS 64.0% 57.9% 50.0%
NA¼not applicable.
Table 3 Endocrine responsiveness and cumulative recurrence-free
survival (RFS) in intermediate risk patients
Responsive Uncertain Non-responsive
A
No. of cases 59 35 15
Case distribution 17% 10% 5%
10-year RFS 91.5% 94.3% 100%
B
No. of cases 32 25 20
Case distribution 9% 7% 6%
10-year RFS 93.8% 87.3% 75.0%
C
No. of cases 85 53 15
Case distribution 25% 16% 5%
10-year RFS 83.5% 65.1% 53.3%
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Figure 3 Intermediate-risk patients.
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sresults were obtained with postoperative tamoxifen monotherapy in
low-risk patients, regardless of endocrine responsiveness. This
confirmed the validity of the recommended therapy for low-risk
breast cancer patients in Japan. Furthermore, compared to low-risk
patients, 10-year RFS was comparable for intermediate-risk patients
with negative lymph node metastasis and only one risk factor or
intermediate-risk patients with negative lymph node metastasis, 2–
5 risk factors, and responsive tumours. Postoperative endocrine
monotherapy appears sufficient in such intermediate-risk patients.
On the other hand, in intermediate-risk patients with positive lymph
node metastasis, unfavourable long-term outcomes were obtained
with postoperative tamoxifen monotherapy. This type of inter-
mediate-risk patients should receive chemotherapy in addition to
endocrine therapy as adjuvant systemic treatment.
In conclusion, patient classifications according to the 2005 St
Gallen guidelines were shown to be valid in Japanese breast cancer
patients. Based on lymph node metastasis and number of risk
factors, it is possible to predict the outcome of each intermediate-
risk patient. This point must be kept in mind when choosing the
drugs for adjuvant systemic therapy.
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